Among the actionable mutations for NSCLC treatment, mutations in EGFR, BRAF, KRAS, NTRK1/2/3, and ALK and ROS1 rearrangements are worth mentioning. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.